300 related articles for article (PubMed ID: 16861913)
1. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
[TBL] [Abstract][Full Text] [Related]
2. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
[TBL] [Abstract][Full Text] [Related]
3. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
[TBL] [Abstract][Full Text] [Related]
4. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.
Le XF; Pruefer F; Bast RC
Cell Cycle; 2005 Jan; 4(1):87-95. PubMed ID: 15611642
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
Marches R; Uhr JW
Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
[TBL] [Abstract][Full Text] [Related]
6. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
Lu Y; Zi X; Pollak M
Int J Cancer; 2004 Jan; 108(3):334-41. PubMed ID: 14648698
[TBL] [Abstract][Full Text] [Related]
8. FOXO1A is a target for HER2-overexpressing breast tumors.
Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
[TBL] [Abstract][Full Text] [Related]
9. Depletion of SUMO ligase hMMS21 impairs G1 to S transition in MCF-7 breast cancer cells.
Ni HJ; Chang YN; Kao PH; Chai SP; Hsieh YH; Wang DH; Fong JC
Biochim Biophys Acta; 2012 Dec; 1820(12):1893-900. PubMed ID: 22906975
[TBL] [Abstract][Full Text] [Related]
10. CDK inhibitors selectively diminish cell cycle controlled activation of the histone H4 gene promoter by p220NPAT and HiNF-P.
Mitra P; Ghule PN; van der Deen M; Medina R; Xie RL; Holmes WF; Ye X; Nakayama KI; Harper JW; Stein JL; Stein GS; van Wijnen AJ
J Cell Physiol; 2009 May; 219(2):438-48. PubMed ID: 19170105
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor alpha inhibits cyclin A expression and retinoblastoma hyperphosphorylation triggered by insulin-like growth factor-I induction of new E2F-1 synthesis.
Shen WH; Yin Y; Broussard SR; McCusker RH; Freund GG; Dantzer R; Kelley KW
J Biol Chem; 2004 Feb; 279(9):7438-46. PubMed ID: 14681231
[TBL] [Abstract][Full Text] [Related]
12. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
13. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.
Le XF; Claret FX; Lammayot A; Tian L; Deshpande D; LaPushin R; Tari AM; Bast RC
J Biol Chem; 2003 Jun; 278(26):23441-50. PubMed ID: 12700233
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21(WAF-1) expression.
Rorke EA; Zhang D; Choo CK; Eckert RL; Jacobberger JW
Exp Cell Res; 2000 Aug; 259(1):149-57. PubMed ID: 10942587
[TBL] [Abstract][Full Text] [Related]
15. Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway.
Langley B; Thomas M; McFarlane C; Gilmour S; Sharma M; Kambadur R
Oncogene; 2004 Jan; 23(2):524-34. PubMed ID: 14724580
[TBL] [Abstract][Full Text] [Related]
16. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.
Lane HA; Motoyama AB; Beuvink I; Hynes NE
Ann Oncol; 2001; 12 Suppl 1():S21-2. PubMed ID: 11521716
[TBL] [Abstract][Full Text] [Related]
17. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of breast cancer cells to radiation by trastuzumab.
Liang K; Lu Y; Jin W; Ang KK; Milas L; Fan Z
Mol Cancer Ther; 2003 Nov; 2(11):1113-20. PubMed ID: 14617784
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Scaltriti M; Eichhorn PJ; Cortés J; Prudkin L; Aura C; Jiménez J; Chandarlapaty S; Serra V; Prat A; Ibrahim YH; Guzmán M; Gili M; Rodríguez O; Rodríguez S; Pérez J; Green SR; Mai S; Rosen N; Hudis C; Baselga J
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3761-6. PubMed ID: 21321214
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes.
Tin AS; Sundar SN; Tran KQ; Park AH; Poindexter KM; Firestone GL
Anticancer Drugs; 2012 Apr; 23(4):370-9. PubMed ID: 22185819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
